A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, May 3, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that John Wayne Cancer Institute in Los Angeles, California and Duke Cancer...
Growing Adoption of CHEMOSAT Permits Expansion Outside of European UnionNEW YORK, April 8, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces...
Quarterly and yearly revenue grow more than 50% compared with 2014NEW YORK, March 21, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic...
NEW YORK, March 7, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at...
Distinguished Physician and Pharmaceutical Industry Executive to Serve as Senior Advisor for Clinical DevelopmentNEW YORK, Feb. 11, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis...
NEW YORK, Feb. 10, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the...
NEW YORK, Feb. 4, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at...
Moffitt Cancer Center Begins Patient Enrollment in FOCUS Trial; Study Results to Support U.S. New Drug ApplicationNEW YORK, Jan. 20, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an...
Agreement Provides Regulatory Pathway for Melphalan/HDS with a Single Phase 3 Trial; Satisfies Substantial Number of Requirements in FDA's September 2013 Complete Response LetterNEW YORK, Jan. 19, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty...
NEW YORK, Jan. 15, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate in...